Replimune: A Misunderstood Contender In Oncolytics
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...
hospitalhealthcare3d
Novel diagnostic tool iFRET helps predict immunotherapy outcomes in melanoma
New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...
Frontiers6d
Using Oncolytic Viruses in Cancer Immunity and Immunotherapy: Hepatocellular Carcinoma, Gastric Cancer, and Colorectal Cancer
Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...
Taiwan News6d
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 ...